NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY
NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY
复制标题
DOI：
--
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
Doreen Agnese;Kimberly H. Allison;Sarah L. Blair;H. Burstein;Anthony D. Elias;Sharon H. Giordano
中科院分区：
文献类型：
--
作者：
Doreen Agnese;Kimberly H. Allison;Sarah L. Blair;H. Burstein;Anthony D. Elias;Sharon H. Giordano
这份来自美国国家综合癌症网络（NCCN）肿瘤临床实践指南的结肠癌部分重点关注转移性结直肠癌（mCRC）的系统治疗方案，因为该部分近期有重要更新。这些更新包括对存在错配修复缺陷/微卫星高度不稳定的mCRC一线使用检查点抑制剂的建议，与生物类似药使用相关的建议，以及对生物标志物检测的扩展建议。系统治疗建议现在包括针对HER2扩增或BRAF V600E突变阳性的mCRC患者的靶向治疗方案。非转移性或可切除/可消融转移性疾病的治疗和管理在NCCN.org上提供的完整版NCCN结肠癌指南中进行了讨论。完整版涵盖的其他主题包括风险评估、分期、病理学、治疗后监测和生存。《美国国家综合癌症网络杂志》2021年；19(3):329 - 359 doi:10.6004/jnccn.2021.0012 NCCN证据和共识类别 类别1：基于高级别证据，NCCN一致认为该干预措施是合适的。类别2A：基于较低级别证据，NCCN一致认为该干预措施是合适的。类别2B：基于较低级别证据，NCCN认为该干预措施是合适的。类别3：基于任何级别的证据，NCCN对于该干预措施是否合适存在重大分歧。除非另有说明，所有建议均为类别2A。临床试验：NCCN认为，对任何癌症患者的最佳管理是在临床试验中。特别鼓励参与临床试验。
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options for the treatment of metastatic colorectal cancer (mCRC), because important updates have recently been made to this section. These updates include recommendations for first-line use of checkpoint inhibitors for mCRC, that is deficient mismatch repair/ microsatellite instability-high, recommendations related to the use of biosimilars, and expanded recommendations for biomarker testing. The systemic therapy recommendations now include targeted therapy options for patients with mCRC that is HER2-amplified, or BRAF V600E mutation–positive. Treatment and management of nonmetastatic or resectable/ablatable metastatic disease are discussed in the complete version of the NCCN Guidelines for Colon Cancer available at NCCN.org. Additional topics covered in the complete version include risk assessment, staging, pathology, posttreatment surveillance, and survivorship. J Natl Compr Canc Netw 2021;19(3):329–359 doi: 10.6004/jnccn.2021.0012 NCCN CATEGORIES OF EVIDENCE AND CONSENSUS Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category2A:Basedupon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate. Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate. All recommendations are category 2A unless otherwise noted. Clinical trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.